• 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 2
    Tsao H,Atkins MB,Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 9981012.
  • 3
    Fang D,Nguyen TK,Leishear K,Finko R,Kulp AN,Hotz S,Van Belle PA,Xu X,Elder DE,Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 932837.
  • 4
    Tsuchida T,Ravindranath MH,Saxton RE,Irie RF. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 1987; 47: 127881.
  • 5
    Kong Y,Li R,Ladisch S. Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1998; 1394: 4356.
  • 6
    Bergelson LD. Serum gangliosides as endogenous immunomodulators. Immunol Today 1995; 16: 4836.
  • 7
    Anichini A,Mortarini R,Nonaka D,Molla A,Vegetti C,Montaldi E,Wang X,Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006; 66: 640511.
  • 8
    Hakansson L,Fredman P,Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J Biochem 1985; 98: 8439.
  • 9
    Valentino LA,Ladisch S. Localization of shed human tumor gangliosides: association with serum lipoproteins. Cancer Res 1992; 52: 81014.
  • 10
    Tonegawa Y,Hakomori SI. “Ganglioprotein and globoprotein”: the glycoproteins reacting with anti-ganglioside and anti-globoside antibodies and the ganglioprotein change associated with transformation. Biochem Biophys Res Commun 1997; 76: 917.
  • 11
    Dolo V,Li R,Dillinger M,Flati S,Manela J,Taylor BJ,Pavan A,Ladisch S. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta 2000; 1486: 26574.
  • 12
    Ravindranath MH,Hsueh EC,Verma M,Ye W,Morton DL. Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J Immunother 2003; 26: 27785.
  • 13
    Perez CA,Ravindranath MH,Soh D,Gonzales A,Ye W,Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002; 8: 38494.
  • 14
    Ravindranath MH,Muthugounder S,Presser N,Ye X,Brosman S,Morton DL. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 2005; 116: 36877.
  • 15
    Santin AD,Ravindranath MH,Bellone S,Muthugounder S,Palmieri M,O'Brien TJ,Roman J,Cannon MJ,Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2004; 111: 61318.
  • 16
    Ravindranath MH,Muthugounder S,Presser N,Selvan SR,Santin AD,Bellone S,Saravanan TS,Morton DL. Immunogenic gangliosides in human ovarian carcinoma. Biochem Biophys Res Commun 2007; 353: 2518.
  • 17
    Ravindranath MH,Wood TF,Soh D,Gonzales A,Muthugounder S,Perez C,Morton DL,Bilchik AJ. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments anti-ganglioside IgM. Cryobiology 2002; 45: 1021.
  • 18
    Chu KU,Ravindranath MH,Gonzales A,Nishimoto K,Tam WY,Soh D,Bilchik A,Katopodis N,Morton DL. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000; 88: 182836.
  • 19
    Dillman R,Selvan S,Schiltz P,Peterson C,Allen K,De Priest C,McClay E,Barth N,Sheehy P,De Leon C,Beutel L. Phase-I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 2004; 19: 65865.
  • 20
    Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 20516.
  • 21
    Nayak SK,Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol 1991; 3: 23742.
  • 22
    Dillman RO,Nayak SK,Beutel LD. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993; 14: 659.
  • 23
    Selvan RS,Pappas TN,Ward FE. Lack of evidence for MHC- unrestricted (atypical) recognition of mucin by mucinous pancreatic tumor-reactive T-cells. Br J Cancer 2000; 82: 691701.
  • 24
    Dillman RO,De Leon C,Beutel LD,Barth NM,Schwartzberg LS,Spitler LE,Garfield DH,O'Connor AA,Nayak SK. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001; 39: 11523.
  • 25
    Selvan SR,Sheridan M,Fowler AW,Dillman RO. Characterization of autologous melanoma cell lines for vaccine therapy: pattern of expression of tumor-associated antigens. Proc Am Assoc Cancer Res 2004; 45: 286.
  • 26
    Nayak SK,Schiltz PM,Dillman RO. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human IFN-γ gene versus incubation with soluble IFN-γ. J Interferon Cytokine Res 1999; 19: 4958.
  • 27
    Van den Aardweg GJ,Naus NC,Verhoeven AC,de Klein A,Luyten GP. Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2002; 43: 25615.
  • 28
    Schiltz PM,Malone C,Spencer KS,Dillman RO. Cryopreserved dendritic cells maintain phenotype and ability to elicit an allogeneic response post recovery. J Immunother 2000; 23: 601.
  • 29
    Tsuchida T,Saxton RE,Morton DL,Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78: 4554.
  • 30
    Ravindranath MH,Tsuchida T,Morton DL,Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991; 67: 302935.
  • 31
    Ravindranath MH,Ravindranath RM,Morton DL,Graves MC. Factors affecting the fine specificity and sensitivity of serum anti-ganglioside antibodies in ELISA. J Immunol Methods 1994; 169: 25772.
  • 32
    Ravindranath MH,Muthugounder S,Saravanan TS,Presser N,Morton DL. Human antiganglioside autoantibodies: validation of ELISA. Ann N Y Acad Sci 2005; 1050: 22942.
  • 33
    Livingston PO,Wong GY,Adluri S,Tao Y,Padavan M,Parente R,Hanlon C,Calves MJ,Helling F,Ritter G,Oettgen HF,Old LJ. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 103644.
  • 34
    Irie RF,Ravindranath MH. Gangliosides as targets for monoclonal antibody therapy of cancer. In: BorrebaeckCAK,LarrickJW, eds. Therapeutic monoclonal antibodies. New York: Stockton, 1990. 7594.
  • 35
    Portoukalian J,Zwingelstein G,Abdul-Malak N,Dore JF. Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun 1978; 85: 91620.
  • 36
    Bernhard H,Meyer zum Buschenfelde KH,Dippold WG. Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer 1989; 44: 15560.
  • 37
    Alessandri G,Filippeschi S,Sinibaldi P,Mornet F,Passera P,Spreafico F,Cappa PM,Gullino PM. Influence of gangliosides on primaryand metastatic neoplastic growth in human and murine cells. Cancer Res 1987; 47: 42437.
  • 38
    Ladisch S,Kitada S,Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987; 79: 187982.
  • 39
    Takahashi K,Ono K,Hirabayashi Y,Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 1988; 140: 32448.
  • 40
    Ravindranath MH,Yesowitch P,Sumobay C,Morton DL. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol 2007; 3: 20114.